Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026
Published: February 03, 2026 by: Market Watch
Sentiment: Negative
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Read More
Novo Nordisk warns of 2026 sales decline, shares fall
Published: February 03, 2026 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in the United States and loss of exclusivity for its blockbuster GLP-1 drugs Wegovy and Ozempic in several markets. For 2026, Novo Nordisk expects adjusted sales and operating profit to decline between 5% and 13% at constant exchange rates, reversing last year's 10% sales growth.
Read More
Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026
Published: February 03, 2026 by: WSJ
Sentiment: Negative
The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%.
Read More
Novo Nordisk shares tumble 11% after company forecasts sales declines this year
Published: February 03, 2026 by: CNBC
Sentiment: Negative
Novo Nordisk said late Tuesday it sees sales and profit growth declining this year, expecting a U.S. sales hit. Novo's American depositary shares fell 11% on the news.
Read More
Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks.
Published: February 03, 2026 by: Barrons
Sentiment: Positive
The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts.
Read More
Novo Nordisk warns of 2026 sales decline
Published: February 03, 2026 by: Reuters
Sentiment: Negative
Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts.
Read More
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Read More
Novo Nordisk releases 2026 sales and operating profit outlook
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
In 2025, Novo Nordisk's sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and
Read More
Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
Published: February 03, 2026 by: Proactive Investors
Sentiment: Neutral
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly's tirzepatide. Novo Nordisk (NYSE:NVO) has reported positive headline results from a late-stage trial of its next-generation diabetes drug CagriSema, but analysts at Citi said the data were largely expected and that more consequential readouts lie ahead.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients
Published: February 02, 2026 by: Reuters
Sentiment: Positive
Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema reduced blood sugar levels and body weight more than semaglutide alone in a late-stage trial of patients with type 2 diabetes.
Read More
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1. CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.
Read More
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.
Read More
Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S has first-mover advantage in obesity pills and aggressive U.S. marketing, supported by a robust cash position, strengthen its competitive stance in the thriving GLP-1 market. Consensus revenue growth forecasts appear overly pessimistic given NVO's historical double-digit growth and Q4 seasonal strength. Despite positives, technical setup, high valuation (PEG 3.3 vs. 1.8 sector median), and potential profit-taking temper enthusiasm make NVO a Hold.
Read More
New play in Denmark charts Novo Nordisk's weight loss boom
Published: January 30, 2026 by: Reuters
Sentiment: Neutral
A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will premiere on Saturday at a theatre outside Copenhagen.
Read More
Novo Nordisk: Investors May Be In For An Earnings Surprise
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such as oral Wegovy's rapid uptake, Lilly's FDA delays, UK approval, and an Amazon partnership have all fueled a 20% rally, but upside appears limited pre-earnings. Management is likely to under promise on 2026 guidance to set up a runway for consistent beats and positive revisions as oral Wegovy's impact materializes, in my view.
Read More
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Read More
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
Published: January 26, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill launched in January 2026 with 18,000+ prescriptions in its debut week, expanding the addressable market to approximately 85 million Americans. Catalent fill-finish site integration is expected to double U.S. supply chain capacity by mid-2026, supporting margin expansion and reducing manufacturing bottlenecks going forward.
Read More
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
Read More
Novo Nordisk: This Run Is Just Getting Started
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S stock has jumped 30% since my last coverage. NVO's first-mover advantage in oral GLP-1 positions it well despite rising competition and pricing pressures in obesity and diabetes markets. The company's long-term prospects are bright, and NVO stock appears undervalued.
Read More
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Published: January 23, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge.
Read More
Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S is poised for a turnaround in 2026, driven by renewed strategic focus under new CEO Maziar Doustdar. NVO's core strengths in diabetes and obesity, particularly with semaglutide, underpin expectations for double-digit revenue and EPS growth. The launch of oral Wegovy, with superior efficacy and tolerability, positions NVO competitively against Eli Lilly's delayed oral GLP-1 entrant.
Read More
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
Read More
Novo: Back From The Dead
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk has rebounded over 40% after a sharp 2025 sell-off, driven by renewed optimism for its oral Wegovy launch. Valuation reset, strong technicals, and an underappreciated pipeline make NVO attractive, especially as it transitions from a single-product to a platform company. Upcoming Q4 results are pivotal, with investor focus on oral Wegovy uptake, manufacturing capacity, and margin trajectory amid competitive and political pressures.
Read More
Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems
Published: January 20, 2026 by: Reuters
Sentiment: Positive
Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a partnership to develop cell-based treatments for diabetes.
Read More
Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.
Read More
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch
Published: January 16, 2026 by: CNBC
Sentiment: Positive
Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S. In a Friday note, TD Cowen analysts called it a "solid start" but cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill.
Read More
Novo Nordisk's Wegovy Weight Loss Shot Approved At Higher Dose in U.K.
Published: January 16, 2026 by: WSJ
Sentiment: Positive
The U.K.'s health regulator approved a higher dose of Novo Nordisk's Wegovy weight-loss drug applicable to patients with a body mass index of at least 30.
Read More
Novo Nordisk obesity pill unlikely to impress early, UBS warns
Published: January 15, 2026 by: Proactive Investors
Sentiment: Neutral
Novo Nordisk (NYSE:NVO) long-awaited obesity pill is unlikely to deliver clear early signals on demand, UBS has warned, even as the Swiss bank raised its price target on the Danish drugmaker's shares by nearly a third. In a note, UBS said that investor focus on initial prescription data for oral Wegovy risked being misplaced, as the figures would not fully capture the early stages of the launch.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406